Transformative Trends Impacting the Cancer In Vitro Diagnostics (IVD) Market Landscape: Technological Advancements In Cancer IVD Testing

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Cancer In Vitro Diagnostics (IVD) Market Size By 2025?
The market size for cancer in vitro diagnostics (IVD) has seen significant growth in the past few years. The market value, which is expected to be $13.36 billion in 2024, is projected to increase to $14.32 billion in 2025, registering a compound annual growth rate (CAGR) of 7.2%. Factors that have contributed to this historical growth include accelerated research into cancer biomarkers, an increase in oncological trials that necessitate testing, expanded government health initiatives, improvement in laboratory infrastructure, and a boost in biotech funding.

How Big Is the Cancer In Vitro Diagnostics (IVD) Market Size Expected to Grow by 2029?
Expectations are high for robust expansion in the cancer in vitro diagnostics (IVD) market in the upcoming years, with predictions of reaching $18.62 billion by 2029, following a compound annual growth rate (CAGR) of 6.8%. The projected growth during the forecasted period can be linked to various factors such as government-led and NGO-driven screening measures, a continually aging demographic, heightened public consciousness regarding early diagnosis of cancer, the broadening of reimbursement procedures, and increased adoption of point-of-care (POC) diagnostics. Principal trends set to shape this forecast period encompass the growth of liquid biopsy technologies, advancements in the next-generation sequencing scope, the amalgamation of artificial intelligence and machine learning disciplines, the incorporation of microfluidics, and the uptake of digital pathology integration.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-in-vitro-diagnostics-ivd-global-market-report

Which Key Market Drivers Powering Cancer In Vitro Diagnostics (IVD) Market Expansion and Growth?
The cancer in vitro diagnostics (IVD) market is anticipated to expand due to the rising prevalence of cancer. Cancer is defined as the unrestrained proliferation and dissemination of abnormal cells in the human body that have the potential to invade adjacent tissues and form tumours. The escalating rates of cancer can be attributed to an aging population, longer lifespan and lower mortality rates from infectious diseases, all leading to a larger group of elderly individuals who are more susceptible to developing cancer. Cancer in vitro diagnostics (IVD) facilitates the fight against cancer by ensuring timely detection, surveillance and management of the disease through lab tests conducted on patient samples. This enables swift decision-making for treatment, thereby enhancing patient outcomes. For instance, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, reported in February 2024 that the number of new cancer cases worldwide escalated to 20 million in 2022 and is predicted to climb up to 35 million by 2050, a surge of 77%. Consequently, the growing prevalence of cancer is fuelling the expansion of the cancer in vitro diagnostics (IVD) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27234&type=smp

What Trends Will Shape the Cancer In Vitro Diagnostics (IVD) Market Through 2029 and Beyond?
Large firms present in the cancer in vitro diagnostics (IVD) market are concentrating on progressing technology, such as the CE in vitro diagnostic (IVD) cancer test kits, with the intention to boost the accessibility, precision, and uniformity of hereditary cancer examinations in diverse clinical environments. CE-in vitro diagnostic (IVD) cancer test kits are diagnostic trials that adhere to the guidelines of the European Union's in vitro diagnostic directive (IVDD), ensuring confirmed performance, safety, and quality for their utilization in patient testing within European laboratories. For example, in February 2022, Invitae, an American company specializing in medical genetics, introduced FusionPlex Dx and LiquidPlex Dx in Europe to amplify its cancer diagnostics collection. FusionPlex Dx provides delicate detection of low-frequency variations in FFPE samples for regular clinical applications. LiquidPlex Dx facilitates non-invasive cancer genomic profiling from blood, yielding quick results and recording tumor heterogeneity, which becomes very useful for customized treatment and disease tracking when tissue samples are restricted.

What Are the Emerging Segments in the Cancer In Vitro Diagnostics (IVD) Market?
The cancer in vitro diagnostics (IVD) market covered in this report is segmented

1) By Product Type: Reagents And Kits, Instruments, Software And Services
2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Microbiology, Molecular Diagnostics, Other Technology
3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer
4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Patient Self-Testing, Other End Users

Subsegments:
1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others
2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others
3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27234&type=smp

Who Are the Global Leaders in the Cancer In Vitro Diagnostics (IVD) Market?
Major companies operating in the cancer in vitro diagnostics (IVD) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., and Tulip Diagnostics (P) Ltd.

Which are the Top Profitable Regional Markets for the Cancer In Vitro Diagnostics (IVD) Industry?
North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (IVD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27234

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.